Clinical trials recruiting for Ovarian Neoplasms
18
Recruiting trials
31
US states with sites
18
Countries
17%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Carboplatin | 2 |
| Pembrolizumab | 2 |
| A2B543 | 1 |
| A2B694 | 1 |
| BMS-936558-01 | 1 |
| BMS-986340 | 1 |
| Bevacizumab | 1 |
| Cisplatin | 1 |
| Cobimetinib | 1 |
| Cyclophosphamide | 1 |
| DM002 | 1 |
| Dabrafenib | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 9 |
| New York | 7 |
| Texas | 7 |
| Florida | 6 |
| Massachusetts | 5 |
| Ohio | 5 |
| Tennessee | 5 |
| Arizona | 4 |
| Minnesota | 4 |
| Michigan | 3 |
| Missouri | 3 |
| New Jersey | 3 |
Top cities
Houston, Texas 6New York, New York 6Boston, Massachusetts 5Los Angeles, California 5Nashville, Tennessee 5Columbus, Ohio 3Grand Rapids, Michigan 3Jacksonville, Florida 3La Jolla, California 3Rochester, Minnesota 3
Self-screener
Recruiting trials
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- A Study of DM002 in Patients With Advanced Solid Tumors
- A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
- DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
- Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques
- Establishment of a Tumor Bank for Blood Samples
- Establishment of a Tumor Bank for Tissue Samples
- Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Related conditions
Trials recruiting for Ovarian Neoplasms often also study these conditions. Each links to its own recruiting-trial list.
Colorectal cancer 1359Pancreatic cancer 870Lung cancer 2180Colorectal Neoplasms 61Breast cancer 2239Non-small cell lung cancer 507Triple Negative Breast Neoplasms 12Stomach Neoplasms 11Lung Neoplasms 33Breast Neoplasms 105
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Ovarian Neoplasms trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.